Business UpdateAug 4, 2026, 06:52 AM
InfuSystem Highlights 2025 Revenue $143.4M, Adj. EBITDA $31.5M
AI Summary
InfuSystem Holdings, Inc. furnished an Investor Presentation dated August 4, 2026, highlighting its strong financial performance for the most recent completed fiscal year 2025. The company reported net revenue of $143.4 million, a 6% increase year-over-year, and adjusted EBITDA of $31.5 million, up 25% year-over-year. The presentation also detailed InfuSystem's scalable home healthcare services platform, growth strategies, and a long-term adjusted EBITDA margin target of 22%-25%.
Key Highlights
- 2025 Net Revenue: $143.4M, a 6% increase year-over-year.
- 2025 Adjusted EBITDA: $31.5M, a 25% increase year-over-year.
- 2025 Adjusted EBITDA Margin: 21.9%, up 3.1% year-over-year.
- Operating Cash Flow for 2025: $24.4M.
- Total Liquidity as of FY 2025: $58.2M.
- Targets long-term Adjusted EBITDA margin of 22%-25%.
- Serves nearly 4,500 customer locations and over 100,000 patients annually.
- Holds approximately 70% market share in oncology ambulatory infusion.
Price Impact
More from INFU